GoodRx Holdings (GDRX) AI Stock Analysis

• Market Cap: $736.54M
• Dividend Yield: N/A
• Average Volume (3M): 4.02M
• Price to Earnings (P/E): 31.7
• Beta (1Y): 0.61
• Revenue Growth: 1.30%
• EPS Growth: N/A
• Country: US
• Employees: 738
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.09
• Shares Outstanding: 108,610,310
• 10 Day Avg. Volume: 2,949,169
• 30 Day Avg. Volume: 4,022,782
• PEG Ratio: 0.31
• Price to Book (P/B): 1.57
• Price to Sales (P/S): 1.21
• P/FCF Ratio: 5.87
• Enterprise Value/Market Cap: 0.73
• Enterprise Value/Revenue: 0.67
• Enterprise Value/Gross Profit: 0.82
• Enterprise Value/Ebitda: 2.90
• 1Y Price Target: $2.82
• Price Target Upside: 29.95% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 12
• EPS Forecast (FY): 0.32
• Revenue Forecast (FY): $764.56M

• Rating: 62 Neutral
• Price Target: $2.50 ▲(15.21% Upside)
• Action: Reiterated Date: 03/07/26
• Date: Action: Reiterated 03/07/26

The score is driven primarily by improved financial stability (profitability rebound, consistent cash generation, and sharply reduced leverage), partially offset by weak price trends and a transitional earnings outlook where 2026 guidance points to revenue/EBITDA declines and continued pressure in the core prescription transactions business. Valuation is supportive but not strong enough to outweigh near-term growth and momentum risks.

Positive Factors

De‑risked balance sheet

GoodRx materially reduced debt and moved leverage to low levels in 2025, ending the year with sizable cash and revolver capacity. Lower leverage increases financial flexibility to fund strategic investments, withstand revenue volatility, and reduces refinancing risk over the next several quarters.

Consistent cash generation

The company has delivered positive operating and free cash flow across recent years, supporting reinvestment into growth initiatives, strategic buybacks, and working capital. Persistent cash generation enhances durability of operations and provides a buffer while management rebalances the business model.

Rapid Pharma Direct growth & platform scale

Pharma Direct's high growth reflects a structural pivot to manufacturer‑driven, higher‑value programs and expands monetization beyond PBM transaction fees. Combined with broad platform reach (hundreds of millions of visits and large user base) and e‑commerce / retail integrations, this diversifies revenue and supports longer‑term margin improvement.

Negative Factors

Weakness in core prescription transactions

The legacy prescription transactions business is contracting, with volume and revenue down. A 6% revenue decline and a 14% drop in monthly active consumers point to persistent engagement and volume challenges that pressure a historically important cash and fee stream over the medium term.

Guidance implies near‑term contraction

Management expects 2026 to be a transition year with both revenue and EBITDA down as it investsto scale Pharma Direct and subscriptions. Planned near‑term declines reduce financial headroom and increase execution risk: growth must offset intentional pullbacks in legacy transaction economics to restore momentum.

Unit economics reset and partner concentration risk

GoodRx negotiated lower per‑transaction fees to secure predictability, creating a structural headwind to revenue and margins. Combined with partner‑specific shocks (Rite Aid/ISP impacts), this exposes the business to concentrated partner risk and subdued take‑rates until new revenue streams scale.

GoodRx Holdings Business Overview & Revenue Model

Company Description

GoodRx Holdings, Inc., through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including subscriptions, pharma manufacturer solutions, and telehealth services. It serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was incorporated in 2015 and is headquartered in Santa Monica, California.

How the Company Makes Money

GoodRx generates revenue through several key streams. The primary source of income comes from the fees it earns when consumers use its platform to obtain discounts on prescription medications. When a user redeems a coupon at a pharmacy, GoodRx receives a transaction fee from the pharmacy or pharmacy benefit manager (PBM). Additionally, GoodRx partners with healthcare providers and telehealth services, earning revenue from telehealth consultations and prescriptions facilitated through its platform. The company also explores advertising opportunities and partnerships with pharmaceutical companies, allowing for additional income through sponsored listings and promotions. These diverse revenue streams contribute to GoodRx's overall earnings, leveraging both consumer engagement and partnerships within the healthcare ecosystem.

GoodRx Holdings Financial Statement Overview

Summary

Fundamentals improved with strong margins, a return to profitability, consistently positive operating/free cash flow, and a materially de-risked balance sheet after sharp debt reduction. The main offset is the sharp 2025 revenue contraction and uneven multi-year profitability/cash conversion, which raises durability risk.

Income Statement

Profitability has improved meaningfully versus earlier years, with net income turning solidly positive in 2025 on very strong gross margins. However, growth is the key concern: revenue fell sharply in 2025 after modest growth in 2024, and profitability has been volatile over the period (losses in 2020–2023 before the recent rebound). The setup suggests a stronger earnings profile today, but with elevated uncertainty around the durability of top-line demand.

Balance Sheet

The balance sheet strengthened materially in 2025, with debt dropping sharply and leverage moving from relatively high levels in 2020–2024 to low debt versus equity in 2025. Equity remains sizable relative to assets, and returns on equity improved significantly in 2025 after being weak/negative in prior years. Main watch-outs are the historically higher leverage and the fact that returns have not been consistently strong year-to-year.

Cash Flow

Cash generation is consistently positive across the period, with healthy operating cash flow and positive free cash flow each year. That said, free cash flow declined in 2025 (after improvement in 2024), and in 2025 cash conversion weakened versus the prior year (operating cash flow and free cash flow were a smaller share of net income than in 2024). Overall, cash flow quality is good, but the recent step-down in cash conversion and free cash flow growth is a near-term risk.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	796.85M	792.32M	750.26M	766.55M	745.42M
Gross Profit	654.13M	744.11M	683.34M	701.48M	698.71M
EBITDA	184.36M	153.92M	108.82M	65.19M	48.00M
Net Income	30.44M	16.39M	-8.87M	-32.83M	-25.25M
Balance Sheet
Total Assets	1.40B	1.39B	1.59B	1.60B	1.61B
Cash, Cash Equivalents and Short-Term Investments	261.82M	448.35M	672.30M	757.16M	941.11M
Total Debt	59.54M	543.39M	711.07M	717.02M	702.33M
Total Liabilities	787.80M	663.41M	826.84M	789.80M	775.95M
Stockholders Equity	616.26M	724.66M	761.96M	814.83M	831.68M
Cash Flow
Free Cash Flow	164.38M	113.55M	82.53M	91.57M	144.32M
Operating Cash Flow	167.90M	183.89M	138.29M	146.78M	178.78M
Investing Cash Flow	-119.96M	-70.35M	-55.77M	-210.50M	-178.73M
Financing Cash Flow	-234.47M	-337.50M	-167.40M	-120.23M	-30.53M

GoodRx Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.17
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GDRX, the sentiment is Negative. The current price of 2.17 is below the 20-day moving average (MA) of 2.23, below the 50-day MA of 2.37, and below the 200-day MA of 3.52, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 44.50 is Neutral, neither overbought nor oversold. The STOCH value of 15.21 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GDRX.

GoodRx Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CCLD	73 Outperform	$151.27M	102.20	18.98%	―	2.97%	―
OMDA	67 Neutral	$820.83M	-72.16	-7.10%	―	50.51%	50.92%
GDRX	62 Neutral	$736.54M	31.72	4.84%	―	1.30%	―
PHR	60 Neutral	$709.58M	78.87	-1.85%	―	14.33%	93.62%
TDOC	53 Neutral	$984.75M	-6.16	-14.24%	―	-2.37%	77.85%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AMWL	46 Neutral	$91.53M	-0.82	-35.88%	―	4.33%	50.50%

GoodRx Holdings Corporate Events

GoodRx Awards Performance-Based Bonus to Chief Accounting Officer

On March 3, 2026, GoodRx Holdings, Inc.’s board of directors approved a discretionary cash bonus of $72,918 for 2025 performance for Romin Nabiey, the company’s chief accounting officer. The award highlights the board’s recognition of executive contributions and reflects the company’s continued use of performance-based compensation to retain and incentivize key financial leadership.

The bonus decision underscores GoodRx’s emphasis on aligning executive rewards with prior-year results and may signal confidence in the company’s financial management. For investors and employees, it offers insight into how the company values its senior accounting function and structures compensation around measurable performance outcomes.

The most recent analyst rating on (GDRX) stock is a Buy with a $3.50 price target. To see the full list of analyst forecasts on GoodRx Holdings stock, see the GDRX Stock Forecast page.

GoodRx Announces Resignation of Board Member Dipanjan Deb

On February 26, 2026, GoodRx Holdings, Inc. disclosed that board member Dipanjan Deb resigned from its Board of Directors, effective the same day. The company reported that Deb’s departure was not due to any disagreement with management or with the company’s policies, operations, or practices, suggesting a routine governance change rather than a sign of internal dispute.

The resignation removes a sitting director from GoodRx’s board but appears unlikely to signal strategic upheaval or immediate operational impact. Stakeholders may view the transition as a standard board refresh, as the company emphasized the absence of conflict or controversy surrounding Deb’s decision to step down.

The most recent analyst rating on (GDRX) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on GoodRx Holdings stock, see the GDRX Stock Forecast page.

GoodRx Approves Retention Bonuses for CEO and CFO

On December 9, 2025, GoodRx Holdings‘ Board of Directors approved retention bonus agreements for CEO Wendy Barnes and CFO Chris McGinnis, offering them cash bonuses of $2 million and $1 million, respectively. These bonuses are contingent upon their continued employment, with repayment conditions if they leave the company under certain circumstances before the end of 2027. The agreements exclude them from participating in the company’s 2025 executive bonus plan or other cash incentive programs for that year.

The most recent analyst rating on (GDRX) stock is a Sell with a $3.00 price target. To see the full list of analyst forecasts on GoodRx Holdings stock, see the GDRX Stock Forecast page.